Come gestire l\u2019osteoporosi in post-menopausa?<\/p>\n
The Endocrine Society USA has published new guidelines. They emphasize increased screening, greater focus on prevention, and particular attention to pharmacological treatment. Which treatment is the most effective?<\/p>\n
1. BISPHOSPHONATES: First-line treatment for postmenopausal osteoporosis.<\/strong><\/p>\n 2.\u00a0Patients with MILD-MODERATE fracture risk, after 3\u20135 years, should consider the possibility of a \"drug holiday,\"<\/strong> meaning a temporary suspension of therapy. The beneficial effects of bisphosphonates are evident even after discontinuation (RESIDUAL EFFECT). For other drug classes, the benefits are lost immediately after therapy is stopped!<\/p>\n 3. MANDIBULAR OSTEONECROSIS: <\/strong>A rare event that occurs only with high doses of bisphosphonates (injectables used in cancer treatment). Currently, major U.S. dental associations have differing recommendations regarding BSF therapy: for instance, the ADA (American Dental Association) generally does not recommend discontinuing BSF treatment in conjunction with dental procedures, while the AAOMS (American Association of Oral and Maxillofacial Surgeons) suggests a drug holiday for a period of 2 months in patients who have been on BSF therapy for more than 4 years. <\/p>\n Bibliography<\/p>\n Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1-28.<\/p>","protected":false},"excerpt":{"rendered":" Come gestire l\u2019osteoporosi in post-menopausa? L\u2019Endocrine Society USA ha pubblicato le nuove linee guida. Un maggiore screening e una maggiore attenzione alla prevenzione, focus particolare al trattamento farmacologico. Quale il pi\u00f9 efficace? 1.BIFOSFONATI, in prima linea nel trattamento dell\u2019osteoporosi post-menopausale 2. Le pazienti con rischio di frattura LIEVE-MODERATA, dopo 3-5 anni, devono prendere in considerazione la […]<\/p>\n","protected":false},"author":1,"featured_media":643,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-642","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie"],"_links":{"self":[{"href":"https:\/\/fenixpharma.it\/en\/wp-json\/wp\/v2\/posts\/642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fenixpharma.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fenixpharma.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fenixpharma.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fenixpharma.it\/en\/wp-json\/wp\/v2\/comments?post=642"}],"version-history":[{"count":2,"href":"https:\/\/fenixpharma.it\/en\/wp-json\/wp\/v2\/posts\/642\/revisions"}],"predecessor-version":[{"id":645,"href":"https:\/\/fenixpharma.it\/en\/wp-json\/wp\/v2\/posts\/642\/revisions\/645"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fenixpharma.it\/en\/wp-json\/wp\/v2\/media\/643"}],"wp:attachment":[{"href":"https:\/\/fenixpharma.it\/en\/wp-json\/wp\/v2\/media?parent=642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fenixpharma.it\/en\/wp-json\/wp\/v2\/categories?post=642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fenixpharma.it\/en\/wp-json\/wp\/v2\/tags?post=642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}